CU20220020A7 - Muteínas derivadas de la interleucina-2 humana con actividad superagonista - Google Patents
Muteínas derivadas de la interleucina-2 humana con actividad superagonistaInfo
- Publication number
- CU20220020A7 CU20220020A7 CU2022000020A CU20220020A CU20220020A7 CU 20220020 A7 CU20220020 A7 CU 20220020A7 CU 2022000020 A CU2022000020 A CU 2022000020A CU 20220020 A CU20220020 A CU 20220020A CU 20220020 A7 CU20220020 A7 CU 20220020A7
- Authority
- CU
- Cuba
- Prior art keywords
- receptor
- beta chain
- superagonist
- human interleukin
- variants
- Prior art date
Links
- 230000002483 superagonistic effect Effects 0.000 title abstract 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 102000055277 human IL2 Human genes 0.000 title 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 241000724791 Filamentous phage Species 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente invención se relaciona con Ia rama de Ia Biotecnología, y se basa en Ia identificación de conjuntos de mutaciones de IL-2 en las proximidades de Ia interfaz con Ia cadena beta de su receptor, a través de Ia selección de variantes provenientes de bibliotecas sobre fagos filamentosos por afinidad al dominio extracelular de Ia cadena beta. Las proteínas recombinantes derivadas de estas variantes muestran un perfil de desarrollabilidad muy favorable, en cuanto a sus altos niveles de expresión, baja tendencia a Ia agregación, y alta estabilidad térmica. Además, en comparación con Ia IL-2 original no mutada, y con otras muteínas superagonistas descritas, tienen una mayor capacidad de estimulación de las poblaciones efectoras del sistema inmune que portan el receptor dimérico de Ia IL-2 y una mayor actividad anti-tumoral <em>in vivo.</em></p>
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2022000020A CU20220020A7 (es) | 2022-03-18 | 2022-03-18 | Muteínas derivadas de la interleucina-2 humana con actividad superagonista |
| PCT/CU2023/050001 WO2023174457A1 (es) | 2022-03-18 | 2023-03-15 | Muteínas derivadas de la interleucina-2 humana con actividad superagonista |
| TW112108466A TW202400630A (zh) | 2022-03-18 | 2023-03-17 | 具有超級促效劑活性之人介白素２衍生的突變蛋白 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2022000020A CU20220020A7 (es) | 2022-03-18 | 2022-03-18 | Muteínas derivadas de la interleucina-2 humana con actividad superagonista |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20220020A7 true CU20220020A7 (es) | 2023-12-07 |
Family
ID=86328873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2022000020A CU20220020A7 (es) | 2022-03-18 | 2022-03-18 | Muteínas derivadas de la interleucina-2 humana con actividad superagonista |
Country Status (3)
| Country | Link |
|---|---|
| CU (1) | CU20220020A7 (es) |
| TW (1) | TW202400630A (es) |
| WO (1) | WO2023174457A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24483B1 (es) | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| US11897930B2 (en) * | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
-
2022
- 2022-03-18 CU CU2022000020A patent/CU20220020A7/es unknown
-
2023
- 2023-03-15 WO PCT/CU2023/050001 patent/WO2023174457A1/es unknown
- 2023-03-17 TW TW112108466A patent/TW202400630A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023174457A1 (es) | 2023-09-21 |
| TW202400630A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robak et al. | Antibiotic treatment–induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia | |
| Stephen-Victor et al. | IL-26: an emerging proinflammatory member of the IL-10 cytokine family with multifaceted actions in antiviral, antimicrobial, and autoimmune responses | |
| Lapa et al. | Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy | |
| Castelo-Branco et al. | The immune system and aging: a review | |
| Miedema et al. | Risk-adapted approach for fever and neutropenia in paediatric cancer patients–a national multicentre study | |
| BR112012012025B8 (pt) | polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusão | |
| CU20220020A7 (es) | Muteínas derivadas de la interleucina-2 humana con actividad superagonista | |
| Kupsa et al. | Baseline serum levels of multiple cytokines and adhesion molecules in patients with acute myeloid leukemia: results of a pivotal trial | |
| Van Raemdonck et al. | CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase | |
| Kim et al. | Identification of a novel angiogenic peptide from periostin | |
| Sawayama et al. | Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma | |
| Domínguez-Rojas et al. | Systemic lupus erythematosus complicated with macrophage activation syndrome mimicking COVID-19 multisystemic inflammatory syndrome in children | |
| Vincent et al. | The sepsis text | |
| Tralongo et al. | Granulocyte colony-stimulating factors (G-CSF) and COVID-19: A double-edged sword | |
| Chougnet et al. | Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS | |
| Gutierrez et al. | A incidência dos sintomas de depressão pós-parto durante a pandemia de COVID-19: The incidence of postpartum depression symptoms during the COVID-19 pandemic | |
| Yuan et al. | Vancomycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) | |
| Motuzova et al. | Development and certification of an industrial reference standard for determination of filgrastim activity | |
| AR093391A1 (es) | POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS | |
| van Veelen et al. | Comment on “Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case–control study from Denmark” | |
| Boehning | Protein S-acylation as a New Paradigm in Cell Signaling | |
| Zekavat et al. | Current strategies against invasive fungal infections in patients with aplastic anemia, strong power and weak weapon, a case report and review of literature | |
| Sleem et al. | Assessment of CXC Motif Chemokine Ligand 10 (CXCL10) Serum Level in Patients with Vitiligo | |
| Antunes et al. | Brucella ovis: invasion, traffic, virulence factors and immune response. | |
| Boudier-Revéret et al. | “Everything Is Relative,” Maybe even Absolute Contraindications |